COVID-19. Coronavirus infection, unspecified
Conditions
Interventions
Intervention 1: Control group: Routine treatment includes hydroxychloroquine 200 mg twice daily for 5 days with acetaminophen 4 mg used during fever and diphenhydramine syrup 10 cc every 8 hours to co
Sponsors
Yazd University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Ages 18 to 60 years Diagnosis of Covid-19 over the past 24 hours Female patients are not exposed to pregnancy and do not become pregnant until thirty days later. Not taking levamisole for the past five days (due to 16-hour drug half-life) Patients suspected to covid-19 based on clinical signs and symptoms of CT scan and candidate for outpatient treatment No medication other than protocol No underlying disease
Exclusion criteria
Exclusion criteria: Hospitalized Patients Patients with hemodynamic instability History of cirrhosis, hepatitis and severe liver disease, severe renal failure (less than 30ml / min) Patients currently taking levamisole for other uses such as parasitic infection Patients with a history of allergic reaction or sensitivity to levamisole Patients receiving chemotherapy for cancer Pregnancy and lactation Ages less than 18 years and over 60 years Patients with underlying diseases including diabetes and hypertension
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Mortality. Timepoint: after completion of the intervention. Method of measurement: Clinical examination.;Side effects that occur during treatment or severe side effects that lead to discontinuation of treatment. Timepoint: Before the intervention, after completion of the intervention. Method of measurement: Clinical examination. | — |
Primary
| Measure | Time frame |
|---|---|
| Clinical symptoms include fever, cough, shortness of breath. Timepoint: Before the intervention, after completion of the intervention. Method of measurement: Clinical examination.;Patients need to be hospitalized. Timepoint: Before the intervention, after completion of the intervention. Method of measurement: Clinical examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmirreza Roustaei Firouzabad
Yazd University of Medical Sciences
Outcome results
None listed